Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Utility of Physiologically Based Pharmacokinetic Modeling in Point of Care Decisions: An Example using Digoxin dosing in Continuous Venovenous Hemodiafiltration.

Srinivasan M, Hirani R, Tsiu M, Kabani K, Chaturvedula A, Palasik B.

Ther Drug Monit. 2019 Sep 30. doi: 10.1097/FTD.0000000000000704. [Epub ahead of print]

PMID:
31593032
2.

An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.

D'Arcy DM, Casey E, Gowing CM, Donnelly MB, Corrigan OI.

BMC Pharmacol Toxicol. 2012 Nov 8;13:14. doi: 10.1186/2050-6511-13-14.

3.

Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration.

Roger C, Muller L, Wallis SC, Louart B, Saissi G, Lipman J, Lefrant JY, Roberts JA.

J Antimicrob Chemother. 2016 Feb;71(2):464-70. doi: 10.1093/jac/dkv349. Epub 2015 Nov 3.

PMID:
26538503
4.

Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.

Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Lefrant JY, Roberts JA.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4901-9. doi: 10.1128/AAC.00828-16. Print 2016 Aug.

5.
6.

Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem.

Cirillo I, Vaccaro N, Balis D, Redman R, Matzke GR.

Antimicrob Agents Chemother. 2011 Mar;55(3):1187-93. doi: 10.1128/AAC.01063-10. Epub 2011 Jan 3.

7.

Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.

Patel K, Roberts JA, Lipman J, Tett SE, Deldot ME, Kirkpatrick CM.

Antimicrob Agents Chemother. 2011 Dec;55(12):5868-73. doi: 10.1128/AAC.00424-11. Epub 2011 Sep 19.

8.

High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration.

Lim SK, Lee SA, Kim CW, Kang E, Choi YH, Park I.

Hemodial Int. 2019 Jan;23(1):69-76. doi: 10.1111/hdi.12704. Epub 2019 Feb 4.

PMID:
30714672
9.

Pharmacokinetic modeling and dosage adaptation of biapenem in Japanese patients during continuous venovenous hemodiafiltration.

Ikawa K, Morikawa N, Ikeda K, Suyama H.

J Infect Chemother. 2008 Feb;14(1):35-9. doi: 10.1007/s10156-007-0572-1. Epub 2008 Feb 24.

PMID:
18297447
10.

Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.

Roberts JA, Udy AA, Bulitta JB, Stuart J, Jarrett P, Starr T, Lassig-Smith M, Roberts NA, Dunlop R, Hayashi Y, Wallis SC, Lipman J.

J Antimicrob Chemother. 2014 Sep;69(9):2508-16. doi: 10.1093/jac/dku177. Epub 2014 May 30.

PMID:
24879665
12.

Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration.

Malone ME, Corrigan OI, Kavanagh PV, Gowing C, Donnelly M, D'Arcy DM.

Int J Antimicrob Agents. 2013 Oct;42(4):335-42. doi: 10.1016/j.ijantimicag.2013.06.011. Epub 2013 Aug 4.

PMID:
23920093
13.

Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration.

Karaiskos I, Friberg LE, Galani L, Ioannidis K, Katsouda E, Athanassa Z, Paskalis H, Giamarellou H.

Int J Antimicrob Agents. 2016 Sep;48(3):337-41. doi: 10.1016/j.ijantimicag.2016.06.008. Epub 2016 Jul 18.

PMID:
27474468
14.

Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.

Roger C, Wallis SC, Louart B, Lefrant JY, Lipman J, Muller L, Roberts JA.

J Antimicrob Chemother. 2016 Jun;71(6):1643-50. doi: 10.1093/jac/dkw043. Epub 2016 Mar 7.

PMID:
26957490
15.

Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients.

Horvatits T, Kitzberger R, Drolz A, Zauner C, Jäger W, Böhmdorfer M, Kraff S, Fritsch A, Thalhammer F, Fuhrmann V, Schenk P.

Antimicrob Agents Chemother. 2014;58(1):94-101. doi: 10.1128/AAC.00892-13. Epub 2013 Oct 21.

16.
17.

Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.

Mariat C, Venet C, Jehl F, Mwewa S, Lazarevic V, Diconne E, Fonsale N, Carricajo A, Guyomarc'h S, Vermesch R, Aubert G, Bidault R, Bertrand JC, Zeni F.

Crit Care. 2006 Feb;10(1):R26.

18.

Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration.

Suyama H, Ikawa K, Morikawa N, Ikeda K, Fujiue Y, Morikawa S, Kaneko K, Kuwabara M, Yamanoue T.

Jpn J Antibiot. 2008 Oct;61(5):303-13.

PMID:
19260350
19.

Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza.

Lemaitre F, Luyt CE, Roullet-Renoleau F, Nieszkowska A, Zahr N, Corvol E, Fernandez C, Antignac M, Farinotti R, Combes A.

Ther Drug Monit. 2012 Apr;34(2):171-5. doi: 10.1097/FTD.0b013e318248672c.

PMID:
22354159
20.

High-Dose Versus Conventional-Dose Continuous Venovenous Hemodiafiltration and Patient and Kidney Survival and Cytokine Removal in Sepsis-Associated Acute Kidney Injury: A Randomized Controlled Trial.

Park JT, Lee H, Kee YK, Park S, Oh HJ, Han SH, Joo KW, Lim CS, Kim YS, Kang SW, Yoo TH, Kim DK; HICORES Investigators.

Am J Kidney Dis. 2016 Oct;68(4):599-608. doi: 10.1053/j.ajkd.2016.02.049. Epub 2016 Apr 12.

PMID:
27084247

Supplemental Content

Support Center